Stay updated on Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.

Latest updates to the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new Revision: v3.4.2 entry was added to the record history, and a lengthy government funding status notice was removed from the page header. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check21 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH Clinical Center status, and updated the record history to Revision: v3.4.1 while removing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check28 days agoChange DetectedUI enhancements include a glossary display option, color-coded change indicators, and an updated revision label.SummaryDifference1%

- Check42 days agoChange DetectedRecord history updated with a new revision entry (v3.3.4) and removal of the previous revision entry (v3.3.3); to avoid alerts for minor changes, set an alert condition.SummaryDifference0.1%

- Check63 days agoChange DetectedNew entries in Record History include a Completed status dated 2025-12-19 and Study Status/Recruitment Status updates on 2025-12-18 (Revision: v3.3.3). Older status details and the HHS Vulnerability Disclosure line were removed.SummaryDifference2%

- Check92 days agoChange DetectedRevision v3.3.2 has been added to the Record History, and Revision v3.2.0 has been removed from the list.SummaryDifference0.1%

Stay in the know with updates to Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.